Trial Profile

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adavosertib (Primary)
Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Prostate cancer; Sarcoma; Solid tumours; Urogenital cancer
Focus Therapeutic Use

Most Recent Events

04 Mar 2023 Status changed from suspended to completed.
05 Dec 2022 Results (n=30) assess the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors published in the Journal of Clinical Oncology
01 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com